Open AccessAtypical onset of bicalutamide-induced liver injury
Author(s) -
Gee Young Yun,
Seok Hyun Kim,
Seok Won Kim,
Jong Seok Joo,
Ju Seok Kim,
Eaum Seok Lee,
Byung Seok Lee,
Sun Hyung Kang,
Hee Seok Moon,
Jae Kyu Sung,
Heon Young Lee,
Kyung Hee Kim
Publication year - 2016
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v22.i15.4062
Subject(s) - bicalutamide , medicine , prostate cancer , gynecomastia , androgen deprivation therapy , antiandrogen , oncology , urology , androgen receptor , endocrinology , cancer
Anti-androgen therapy is the leading treatment for advanced prostate cancer and is commonly used for neoadjuvant or adjuvant treatment. Bicalutamide is a non-steroidal anti-androgen, used during the initiation of androgen deprivation therapy along with a luteinizing hormone-releasing hormone agonist to reduce the symptoms of tumor-related flares in patients with advanced prostate cancer. As side effects, bicalutamide can cause fatigue, gynecomastia, and decreased libido through competitive androgen receptor blockade. Additionally, although not as common, drug-induced liver injury has also been reported. Herein, we report a case of hepatotoxicity secondary to bicalutamide use. Typically, bicalutamide-induced hepatotoxicity develops after a few days; however, in this case, hepatic injury occurred 5 mo after treatment initiation. Based on this rare case of delayed liver injury, we recommend careful monitoring of liver function throughout bicalutamide treatment for prostate cancer.